Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer-Reference-Cited by-同舟云学术

Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer

Published:2019-02-22 Issue:3 Volume:110 Page:1032-1043
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Denda Tadamichi¹^ORCID,Sakai Daisuke²^ORCID,Hamaguchi Tetsuya³,Sugimoto Naotoshi⁴,Ura Takashi⁵,Yamazaki Kentaro⁶,Fujii Hirofumi⁷,Kajiwara Takeshi⁸,Nakajima Takako Eguchi⁹,Takahashi Shin¹⁰,Otsu Satoshi¹¹,Komatsu Yoshito¹²,Nagashima Fumio¹³,Moriwaki Toshikazu¹⁴^ORCID,Esaki Taito¹⁵^ORCID,Sato Takeo¹⁶,Itabashi Michio¹⁷,Oki Eiji¹⁸,Sasaki Toru¹⁹,Sunaga Yoshinori²⁰,Ziti-Ljajic Samira²¹,Brillac Claire²²,Yoshino Takayuki²³

Affiliation:

1. Department of Gastroenterology; Chiba Cancer Center; Chiba Japan

2. Department of Frontier Science for Cancer and Chemotherapy; Osaka University Graduate School of Medicine; Suita Japan

3. Department of Gastrointestinal Medical Oncology; National Cancer Center Hospital; Tokyo Japan

4. Department of Medical Oncology; Osaka Medical Center for Cancer and Cardiovascular Disease; Osaka Japan

5. Department of Clinical Oncology; Aichi Cancer Center Hospital; Nagoya Japan

6. Department of Gastrointestinal Oncology; Shizuoka Cancer Center; Shizuoka Japan

7. Department of Clinical Oncology; Jichi Medical University Hospital; Shimotsuke Japan

8. Department of Gastrointestinal Medical Oncology; Shikoku Cancer Center; Matsuyama Japan

9. Department of Medical Oncology; St. Marianna University School of Medical Hospital; Kawasaki Japan

10. Department of Medical Oncology; Tohoku University Hospital; Sendai Japan

11. Department of Medical Oncology; Oita University Hospital; Yufu Japan

12. Department of Cancer Center; Hokkaido University Hospital; Sapporo Japan

13. Department of Medical Oncology; Kyorin University Hospital; Mitaka Japan

14. Department of Gastroenterology; University of Tsukuba Hospital; Tsukuba Japan

15. Department of Gastrointestinal and Medical Oncology; National Kyushu Cancer Center; Fukuoka Japan

16. Department of Gastrointestinal Surgery; Kitasato University East Hospital; Sagamihara Japan

17. Department of Surgery 2; Tokyo Women's Medical University Hospital; Tokyo Japan

18. Department of Gastrointestinal Surgery; Kyushu University Hospital; Fukuoka Japan

19. Local Medical Operation; Sanofi K. K.; Tokyo Japan

20. Biostatstics& Programming; Sanofi K. K.; Tokyo Japan

21. Pharmacokinetics; Sanofi Oncology; Alfortville France

22. Modeling& Simulation; Sanofi Oncology; Alfortville France

23. Department of Gastrointestinal Oncology; National Cancer Center Hospital East; Kashiwa Japan

Funder

Sanofi

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13943/fullpdf

Reference22 articles.

1. The Global Cancer Observatory, International Agency for Research on Cancer 2018 http://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf

2. The Global Cancer Observatory, International Agency for Research on Cancer http://gco.iarc.fr/today/data/factsheets/populations/392-japan-fact-sheets.pdf

3. Center for Cancer Control and Information Services, National Cancer Center Japan. Projected Cancer Statistics 2018 https://ganjoho.jp/en/public/statistics/short_pred.html

4. American Cancer Society, Inc. What are the survival rates for colorectal cancer, by stage? http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-survival-rates

5. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer;Takahashi;Cancer Res,1995

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter, prospective, phase II trial of second‐line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti‐EGFR antibody: HGCSG1801;International Journal of Cancer;2024-08-14

2. Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies;Journal of Cancer Research and Clinical Oncology;2024-05-08

3. Research Progress in the Treatment of Colorectal Cancer;Advances in Clinical Medicine;2024

4. Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis;Medicine;2023-09-01

5. A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety;Critical Reviews in Oncology/Hematology;2023-08